Admedus Limited announced the complete transfer of its unique Sterilisation Method as part of its ADAPT tissue treatment process to 4C Medical Technologies Inc. (4C Medical). 4C Medical is a Minnesota-based developer of AltaValveTM, a minimally invasive device for mitral valve repair. The technology transfer follows 4C Medical validating the process. As per the Admedus supply agreement with 4C Medical, 4C Medical will pay an additional $1 million ($0.44 million previously received) to use the technology to sterilise the ADAPT® tissue incorporated in its transcatheter mitral valve replacement (TMVR) AltaValveTM system device. The 4C Medical implant utilises tissue processed by Admedus' clinically superior ADAPT® Tissue Engineering Process for the functioning leaflet component of its valve. It will benefit from this technology to optimise function and durability.